COMMUNIQUÉS West-GlobeNewswire

Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
30/11/2018
EDIT-101 set to be the first in vivo CRISPR medicine administered to people anywhere in the world Earns $25 million milestone for IND acceptance from partner Allergan CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) -- [...]
Neos Therapeutics Announces Realignment of Commercial Organization
30/11/2018
– Strategic assessment leads to new salesforce structure and is expected to accelerate path to profitability – – Company to host conference call today at 8:30am ET – DALLAS and FORT WORTH, Texas, Nov. 30, 2018 (GLOBE [...]
Emerald Health Therapeutics Reports 3rd Quarter 2018 Financial Results and Provides Corporate Update
30/11/2018
Continued production expansion, successful supply fulfillment and product diversification position Emerald for revenue growth VICTORIA, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, [...]
Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting
30/11/2018
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted four [...]
Lundbeck and Otsuka report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
30/11/2018
Valby, Nov. 30, 2018 (GLOBE NEWSWIRE) -- The combination treatment arm of brexpiprazole and sertraline demonstrated improvement in symptoms of PTSD versus placebo (p<0.01) on the primary efficacy endpoint The [...]
La FDA américaine approuve le test de mutation LeukoStrat CDx FLT3 d’Invivoscribe comme CDx et le médicament XOSPATA (fumarate de gilteritinib) d’Astellas pour le traitement des patients atteints de LMA aux États-Unis
30/11/2018
Invivoscribe a également obtenu le remboursement national pour le test CDx au Japon SAN DIEGO, 30 nov. 2018 (GLOBE NEWSWIRE) -- Invivoscribe est heureuse d’annoncer l’approbation par la FDA du test de mutation [...]
Aino Health AB (publ): Aino Health and Finla in joint client project
30/11/2018
November 30, 2018 Aino Health's strategic partner Finla has concluded an agreement with a global player in the process industry regarding Aino HealthManager. The collaboration will begin with 1,700 new subscriptions to [...]
Shire Receives European Approval for TAKHZYRO™ (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioedema
30/11/2018
Intended for Global Audience Shire Receives European Approval for TAKHZYRO™ (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioedema - TAKHZYRO is the first monoclonal antibody for the [...]
Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2018
30/11/2018
SECOND QUARTER August 1 – October 31, 2018 Consolidated net sales amounted to TSEK 158 compared to TSEK 1,651 in the second quarter the previous year Operating loss was TSEK 22,627 compared to TSEK 22,129 in the second [...]
Eckert & Ziegler BEBIG to restructure its implant business
30/11/2018
Press release Inside and regulated information 30 November 2018, 7:45 (CET) Seneffe, 30 November 2018. Today, the management of Eckert & Ziegler BEBIG SA decided that as of mid-2019, it will focus more strongly on [...]
Eckert & Ziegler BEBIG réorganise son secteur des implants
30/11/2018
Communiqué de presse Information privilégiée et réglementée 30 Novembre 2018, 7:45 (CET) Seneffe, le 30 Novembre 2018. La direction de la société Eckert & Ziegler BEBIG SA a décidé aujourd'hui de se concentrer [...]
ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 23rd tranche of investment today
30/11/2018
Amsterdam, The Netherlands - 30 November 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 23 rd Tranche of EUR 220,000 is issued as a private placement of 22 convertible notes (the " [...]
INNATE PHARMA : Publication of monalizumab research in the prestigious "Cell" journal
30/11/2018
Innate Pharma announces publication of monalizumab research in the prestigious "Cell" journal widening the horizon of immune checkpoint inhibitors Monalizumab is a first-in-class broad-spectrum immune checkpoint [...]
Innate Pharma: Publication, dans la prestigieuse revue scientifique « Cell », de travaux de recherche sur monalizumab
30/11/2018
Innate Pharma annonce la publication, dans lA prestigieuse revue scientifique « cell », de travaux de recherche sur monalizumab qui Élargissent l'horizon des inhibiteurs de points de contrôle immunitaire Monalizumab est [...]
Lexington Announces Q3 2018 Financial Results and Non-Brokered Private Placement
30/11/2018
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, British Columbia, Nov. 29, 2018 (GLOBE NEWSWIRE [...]
Oncology Venture enters into financing agreement
30/11/2018
Company Announcement Oncology Venture A/S enters into a financing agreement based on the issuance of convertible notes and warrants Hoersholm, Denmark, November 30, 2018 – Oncology Venture A/S (Nasdaq First North [...]
Update -- US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
30/11/2018
Invivoscribe also Receives National Reimbursement for CDx Assay in Japan SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and [...]
EDAP TMS SA : EDAP Announces Expiration of Second and Final Tranche of Outstanding Warrants
29/11/2018
Warrants for 1.5 Million Ordinary Shares in the Form of American Depository Shares Expired on November 29, 2018 Capital Structure Now Comprised Exclusively of Common Stock LYON, France, November 29, 2018 -- EDAP TMS SA [...]
PhaseBio Reports Third Quarter 2018 Financial and Business Results
29/11/2018
Closed initial public offering that raised $43.0 million in net proceeds Demonstrated proof of concept for PB2452, supporting continued development for the reversal of antiplatelet activity of ticagrelor MALVERN, Pa. [...]

Pages